Global Lower Back Pain Market, By Disease Type (Acute, Sub-Acute, Chronic), Type (Diagnosis, Treatment), End User (Hospitals, Orthopaedic Clinics, Ambulatory Surgery Centres, Others), Distribution Channel (Direct, Retail) – Industry Trends and Forecast to 2029
Lower Back Pain Market Analysis and Size
Acute low back pain can be treated for the underlying reason or the initial damage, but chronic low back pain must last for 12 weeks or more. Chronic low back pain is lower back discomfort that lasts longer than three months. This condition can be caused by an injury, illness, or stress on various body parts. The pain can vary greatly and manifest as bone pain, muscle pain, or nerve pain.
Data Bridge Market Research analyses that the lower back pain market which was USD 8,812.01 million in 2021, would rocket up to USD 13421.46 million by 2029, and is expected to undergo a CAGR of 5.40% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Lower Back Pain Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Disease Type (Acute, Sub-Acute, Chronic), Type (Diagnosis, Treatment), End User (Hospitals, Orthopaedic Clinics, Ambulatory Surgery Centres, Others), Distribution Channel (Direct, Retail)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), Johnson & Johnson Private Limited (U.S.), Sanofi (France), Endo Pharmaceuticals Inc. (Ireland), Merck & Co Inc. (U.S.), Dr. Reddy’s Laboratories Ltd. (India), Vertebral Technologies, Inc. (U.S.), Medtronic (Ireland), Boston Scientific Corporation (U.S.), BioWave Corporation, Koninklijke Philips N.V. (Netherlands), Astellas Pharma Inc. (Japan), SpineThera Inc. (U.S.), CELGENE CORPORATION (U.S.), Teva Pharmaceutical Industries Ltd. (Israel)
|
|
Market Opportunities
|
|
Market Definition
Nearly everyone has experienced lower back discomfort at some point. Basically, it is a sort of muscle tension, pain, or rigidity that is present above the gluteal sulcus and below the bottom margin of the rib cage. It may be brought on by a strain (injury) to the back's muscles or tendons, arthritis, structural issues, or disc injuries. There are three different types of low back pain: acute, subacute, and chronic.
Lower Back Pain Market Dynamics
Drivers
- Increase in nerve cases
Demand for the lower back pain market is anticipated to be driven by an inactive lifestyle and an increase in nerve cases. The increased use of novel antidepressants and the rising elderly population are additional significant factors driving the market's expansion. Within the forecast period, the market is expected to experience new, attractive growth prospects due to rising research and development, particularly in the area of lower back pain.
- Rise in anti-inflammatory medications
Anti-inflammatory medications' negligible adverse effects are encouraging a rise in their use as painkillers. The effectiveness of pharmaceuticals like diclofenac, ibuprofen, and naproxen as non-steroidal anti-inflammatory treatments is aiding the industry's growth. Additionally, the lower doses of these medications are commonly accessible without a doctor's prescription. The market for lower back pain is anticipated to rise as a result of market participants' efforts to create novel NSAIDs that would lessen patients' pain.
- Rising number of individuals
The expansion of the market is being aided by the rising number of individuals in the area who suffer from persistent lower back pain. The market growth for chronic lower back pain treatment in North America is quickening due to rising healthcare spending by the populace and the presence of cutting-edge healthcare infrastructure. In the upcoming years, it is projected that growing research efforts to identify the root causes of chronic lower back pain and create better treatment alternatives will spur market expansion.
Opportunities
The primary growth drivers for the chronic lower back pain market are an increase in the frequency of nerve instances and an increase in the senior population. For instance, the National Institute of Neurological disorders and stroke reports that roughly 80% of adults have this type of low back discomfort at some point in their lives. Inactivity, expanding healthcare awareness in developed and developing nations, and rising consumer disposable income are further factors anticipated to promote market expansion.
Restraints/Challenges
On the other hand, the high cost associated with drug development will obstruct the market's growth rate. The stringent regulatory policies will also restrain the market growth rate during the forecast period of 2022-2029.
This lower back pain market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lower back pain market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Lower Back Pain Market
As older patients make up a large portion of COVID-19 patients with severe symptoms, these older patients frequently endure chronic pain even in the absence of COVID-19 infection. Thus, the virus may not be to blame for the increased neurologic symptoms. The reported increase in discomfort among COVID-19 patients might simply be a temporary ailment. Similar to the flu, the pain would only become noticeable during the acute infection. The accounts of post-COVID condition would not be explained by this, though.
Global Lower Back Pain Market Scope
The lower back pain market is segmented on the basis of disease type, type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Disease Type
- Acute
- Sub-Acute
- Chronic
Type
- Diagnosis
- Treatment
End User
- Hospitals
- Orthopaedic Clinics
- Ambulatory Surgery Centres
- Others
Distribution Channel
- Direct
- Retail
Lower Back Pain Market Regional Analysis/Insights
The lower back pain market is analysed and market size insights and trends are provided by country, disease type, type, end user and distribution channel as referenced above.
The countries covered in the lower back pain market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the lower back pain market due to increased awareness over the availability of different treatment procedures.
Asia-Pacific is anticipated to have a fastest growth rate in the forecast period of 2022 to 2029 due to the rapidly growing expenditure on healthcare facilities by government and increasing geriatric population.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Lower Back Pain Market Share Analysis
The lower back pain market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lower back pain market.
Some of the major players operating in the lower back pain market are:
- Pfizer Inc (U.S.)
- Johnson & Johnson Private Limited (U.S.)
- Sanofi (France)
- Endo Pharmaceuticals Inc. (Ireland)
- Merck & Co Inc. (U.S.)
- Dr. Reddy’s Laboratories Ltd. (India)
- Vertebral Technologies, Inc. (U.S.)
- Medtronic (Ireland)
- Boston Scientific Corporation (U.S.)
- BioWave Corporation
- Koninklijke Philips N.V. (Netherlands)
- Astellas Pharma Inc. (Japan)
- SpineThera Inc. (U.S.)
- CELGENE CORPORATION (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
SKU-